

# Walter Maetzler

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5241387/walter-maetzler-publications-by-year.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

291  
papers

11,506  
citations

52  
h-index

97  
g-index

324  
ext. papers

14,481  
ext. citations

5.5  
avg. IF

6  
L-index

#	Paper	IF	Citations
291	Therapeutic climbing in Parkinson's disease: Differences in self-reported health and well-being, feasibility and clinical changes.. <i>Physiotherapy Theory and Practice</i> , <b>2022</b> , 1-15	1.5	0
290	Functional Movement Disorder in Older Adults. <i>Current Clinical Neurology</i> , <b>2022</b> , 197-203	0.1	0
289	Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy: New Data and Quantitative Meta-Analysis.. <i>Frontiers in Aging Neuroscience</i> , <b>2022</b> , 14, 783996	5.3	1
288	Reliability of IMU-Derived Temporal Gait Parameters in Neurological Diseases.. <i>Sensors</i> , <b>2022</b> , 22,	3.8	2
287	Postural Sway in Parkinson's Disease and Multiple Sclerosis Patients During Tasks With Different Complexity.. <i>Frontiers in Neurology</i> , <b>2022</b> , 13, 857406	4.1	
286	Improving functional disability in patients with tremor: A clinical perspective of the efficacies, considerations, and challenges of assistive technology.. <i>Journal of the Neurological Sciences</i> , <b>2022</b> , 435, 120197	3.2	0
285	Plasma autoantibodies to glial fibrillary acidic protein (GFAP) react with brain areas according to Braak staging of Parkinson's disease.. <i>Journal of Neural Transmission</i> , <b>2022</b> , 1	4.3	
284	The longevity gene Klotho and its cerebrospinal fluid protein profiles as a modifier for Parkinson's disease. <i>European Journal of Neurology</i> , <b>2021</b> , 28, 1557-1565	6	2
283	Autonomic Symptoms in Older Adults Are Common and Associated With Health-Related Quality of Life. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 757748	4.1	0
282	Effect of Fear of Falling on Mobility Measured During Lab and Daily Activity Assessments in Parkinson's Disease.. <i>Frontiers in Aging Neuroscience</i> , <b>2021</b> , 13, 722830	5.3	1
281	Technical validation of real-world monitoring of gait: a multicentric observational study. <i>BMJ Open</i> , <b>2021</b> , 11, e050785	3	8
280	Walking on common ground: a cross-disciplinary scoping review on the clinical utility of digital mobility outcomes. <i>Npj Digital Medicine</i> , <b>2021</b> , 4, 149	15.7	6
279	Digital assessment at home - mPower against Parkinson disease. <i>Nature Reviews Neurology</i> , <b>2021</b> , 17, 661-662	15	0
278	Arm swing responsiveness to dopaminergic medication in Parkinson's disease depends on task complexity. <i>Npj Parkinson's Disease</i> , <b>2021</b> , 7, 89	9.7	0
277	Increased functional connectivity in a population at risk of developing Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2021</b> , 92, 1-6	3.6	1
276	Association of Hippocampal Subfields, CSF Biomarkers, and Cognition in Patients With Parkinson Disease Without Dementia. <i>Neurology</i> , <b>2021</b> , 96, e904-e915	6.5	2
275	Gait speed in clinical and daily living assessments in Parkinson's disease patients: performance versus capacity. <i>Npj Parkinson's Disease</i> , <b>2021</b> , 7, 24	9.7	12

274	Initial center of pressure position prior to anticipatory postural adjustments during gait initiation in people with Parkinson's disease with freezing of gait. <i>Parkinsonism and Related Disorders</i> , <b>2021</b> , 84, 8-14	3.6	5
273	How COVID-19 will boost remote exercise-based treatment in Parkinson's disease: a narrative review. <i>Npj Parkinson's Disease</i> , <b>2021</b> , 7, 25	9.7	21
272	Age-related deterioration of performance and increase of cortex activity comparing time- versus item-controlled fNIRS measurement. <i>Scientific Reports</i> , <b>2021</b> , 11, 6766	4.9	0
271	Neurofilament light chain is a cerebrospinal fluid biomarker in hereditary spastic paraplegia. <i>Annals of Clinical and Translational Neurology</i> , <b>2021</b> , 8, 1122-1131	5.3	1
270	βSynuclein in Plasma-Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease. <i>Movement Disorders</i> , <b>2021</b> , 36, 2508-2518	7	3
269	Short-term physical exercise impacts on the human holobiont obtained by a randomised intervention study. <i>BMC Microbiology</i> , <b>2021</b> , 21, 162	4.5	6
268	Comparison of Laboratory and Daily-Life Gait Speed Assessment during ON and OFF States in Parkinson's Disease. <i>Sensors</i> , <b>2021</b> , 21,	3.8	1
267	A randomised controlled trial on effectiveness and feasibility of sport climbing in Parkinson's disease. <i>Npj Parkinson's Disease</i> , <b>2021</b> , 7, 49	9.7	1
266	Gut Microbiome Signatures of Risk and Prodromal Markers of Parkinson Disease. <i>Annals of Neurology</i> , <b>2021</b> , 90, E1-E12	9.4	7
265	Cognitive impairment and sedentary behavior predict health-related attrition in a prospective longitudinal Parkinson's disease study. <i>Parkinsonism and Related Disorders</i> , <b>2021</b> , 82, 37-43	3.6	1
264	Modernizing Daily Function Assessment in Parkinson's Disease Using Capacity, Perception, and Performance Measures. <i>Movement Disorders</i> , <b>2021</b> , 36, 76-82	7	10
263	Toward e-Scales: Digital Administration of the International Parkinson and Movement Disorder Society Rating Scales. <i>Movement Disorders Clinical Practice</i> , <b>2021</b> , 8, 208-214	2.2	2
262	Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease. <i>Movement Disorders</i> , <b>2021</b> , 36, 963-976	7	11
261	Phenylalanine Effects on Brain Function in Adult Phenylketonuria. <i>Neurology</i> , <b>2021</b> , 96, e399-e411	6.5	8
260	Everyday Function in Alzheimer's and Parkinson's Patients with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , <b>2021</b> , 79, 197-209	4.3	3
259	Effects of Levodopa on quality of sleep and nocturnal movements in Parkinson's Disease. <i>Journal of Neurology</i> , <b>2021</b> , 268, 2506-2514	5.5	5
258	The Mutation Matters: CSF Profiles of GCase, Sphingolipids, βSynuclein in PD. <i>Movement Disorders</i> , <b>2021</b> , 36, 1216-1228	7	12
257	Cerebellar rTMS in PSP: a Double-Blind Sham-Controlled Study Using Mobile Health Technology. <i>Cerebellum</i> , <b>2021</b> , 20, 662-666	4.3	3

256	Validation of IMU-based gait event detection during curved walking and turning in older adults and Parkinson's Disease patients. <i>Journal of NeuroEngineering and Rehabilitation</i> , <b>2021</b> , 18, 28	5.3	11
255	Reliability of IMU-Derived Static Balance Parameters in Neurological Diseases. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 18,	4.6	4
254	Proposed Mobility Assessments with Simultaneous Full-Body Inertial Measurement Units and Optical Motion Capture in Healthy Adults and Neurological Patients for Future Validation Studies: Study Protocol. <i>Sensors</i> , <b>2021</b> , 21,	3.8	2
253	The Power of Musification: Sensor-Based Music Feedback Improves Arm Swing in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , <b>2021</b> , 8, 1240-1247	2.2	0
252	Postural transitions detection and characterization in healthy and patient populations using a single waist sensor. <i>Journal of NeuroEngineering and Rehabilitation</i> , <b>2020</b> , 17, 70	5.3	9
251	The detection of age groups by dynamic gait outcomes using machine learning approaches. <i>Scientific Reports</i> , <b>2020</b> , 10, 4426	4.9	11
250	Executive Function Is Related to the Urinary Urgency in Non-demented Patients With Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , <b>2020</b> , 12, 55	5.3	2
249	Evaluating the Use of Circulating MicroRNA Profiles for Lung Cancer Detection in Symptomatic Patients. <i>JAMA Oncology</i> , <b>2020</b> , 6, 714-723	13.4	42
248	Does increased forefoot load contribute to freezing of gait in Parkinson's disease? A clinical observation. <i>Parkinsonism and Related Disorders</i> , <b>2020</b> , 77, 83-84	3.6	
247	Motor, cognitive and mobility deficits in 1000 geriatric patients: protocol of a quantitative observational study before and after routine clinical geriatric treatment - the ComOn-study. <i>BMC Geriatrics</i> , <b>2020</b> , 20, 45	4.1	7
246	Interrelation between Sarcopenia and the Number of Motor Neurons in Patients with Parkinsonian Syndromes. <i>Gerontology</i> , <b>2020</b> , 66, 409-415	5.5	7
245	Long-term unsupervised mobility assessment in movement disorders. <i>Lancet Neurology</i> , <b>2020</b> , 19, 462-470	24.1	74
244	Rare Variants in Specific Lysosomal Genes Are Associated With Parkinson's Disease. <i>Movement Disorders</i> , <b>2020</b> , 35, 1245-1248	7	23
243	Intraindividual Neurofilament Dynamics in Serum Mark the Conversion to Sporadic Parkinson's Disease. <i>Movement Disorders</i> , <b>2020</b> , 35, 1233-1238	7	10
242	Systematic Review Looking at the Use of Technology to Measure Free-Living Symptom and Activity Outcomes in Parkinson's Disease in the Home or a Home-like Environment. <i>Journal of Parkinson's Disease</i> , <b>2020</b> , 10, 429-454	5.3	20
241	Protocol for PD SENSORS: Parkinson's Disease Symptom Evaluation in a Naturalistic Setting producing Outcome measuRes using SPHERE technology. An observational feasibility study of multi-modal multi-sensor technology to measure symptoms and activities of daily living in Parkinson's disease. <i>BMJ Open</i> , <b>2020</b> , 10, e041303	3	4
240	Neurogeriatrics-a vision for improved care and research for geriatric patients with predominating neurological disabilities. <i>Zeitschrift Fur Gerontologie Und Geriatrie</i> , <b>2020</b> , 53, 340-346	2.7	1
239	Private variants in PRKN are associated with late-onset Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2020</b> , 75, 24-26	3.6	2

238	Association of cognitive activities of daily living (ADL) function and nonmotor burden in nondemented Parkinson's disease patients. <i>Neuropsychology</i> , <b>2020</b> , 34, 447-455	3.8	4
237	Parkinson's Disease: Glucocerebrosidase 1 Mutation Severity Is Associated with CSF Alpha-Synuclein Profiles. <i>Movement Disorders</i> , <b>2020</b> , 35, 495-499	7	22
236	Walking-related digital mobility outcomes as clinical trial endpoint measures: protocol for a scoping review. <i>BMJ Open</i> , <b>2020</b> , 10, e038704	3	8
235	Wearable Health Technology to Quantify the Functional Impact of Peripheral Neuropathy on Mobility in Parkinson's Disease: A Systematic Review. <i>Sensors</i> , <b>2020</b> , 20,	3.8	4
234	Common diseases alter the physiological age-related blood microRNA profile. <i>Nature Communications</i> , <b>2020</b> , 11, 5958	17.4	16
233	Insulin sensitivity predicts cognitive decline in individuals with prediabetes. <i>BMJ Open Diabetes Research and Care</i> , <b>2020</b> , 8,	4.5	13
232	Gait Analysis with Wearables Can Accurately Classify Fallers from Non-Fallers: A Step toward Better Management of Neurological Disorders. <i>Sensors</i> , <b>2020</b> , 20,	3.8	4
231	Classification of Neurological Patients to Identify Fallers Based on Spatial-Temporal Gait Characteristics Measured by a Wearable Device. <i>Sensors</i> , <b>2020</b> , 20,	3.8	5
230	Implementation of Mobile Health Technologies in Clinical Trials of Movement Disorders: Underutilized Potential. <i>Neurotherapeutics</i> , <b>2020</b> , 17, 1736-1746	6.4	9
229	Quantification of Arm Swing during Walking in Healthy Adults and Parkinson's Disease Patients: Wearable Sensor-Based Algorithm Development and Validation. <i>Sensors</i> , <b>2020</b> , 20,	3.8	4
228	Toward a Regulatory Qualification of Real-World Mobility Performance Biomarkers in Parkinson's Patients Using Digital Mobility Outcomes. <i>Sensors</i> , <b>2020</b> , 20,	3.8	11
227	Distinct Relationship Between Cognitive Flexibility and White Matter Integrity in Individuals at Risk of Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , <b>2020</b> , 12, 250	5.3	0
226	Assessment of cognitive-driven activity of daily living impairment in non-demented Parkinson's patients. <i>Journal of Neuropsychology</i> , <b>2020</b> , 14, 69-84	2.6	9
225	Gut Microbiome Signatures of Risk and Prodromal Markers of Parkinson Disease. <i>Annals of Neurology</i> , <b>2020</b> , 88, 320-331	9.4	32
224	Reply to "Quantitative Motor Functioning in Prodromal Parkinson Disease". <i>Annals of Neurology</i> , <b>2019</b> , 86, 981-982	9.4	
223	Alterations in Blood Monocyte Functions in Parkinson's Disease. <i>Movement Disorders</i> , <b>2019</b> , 34, 1711-1721	7.1	33
222	Dual vs. Single Tasking During Circular Walking: What Better Reflects Progression in Parkinson's Disease?. <i>Frontiers in Neurology</i> , <b>2019</b> , 10, 372	4.1	4
221	Linking pre-existing biorepositories for medical research: the PopGen 2.0 Network. <i>Journal of Community Genetics</i> , <b>2019</b> , 10, 523-530	2.5	4

220	Dementia with lewy bodies: GBA1 mutations are associated with cerebrospinal fluid alpha-synuclein profile. <i>Movement Disorders</i> , <b>2019</b> , 34, 1069-1073	7	18
219	Functional movement disorders in neurogeriatric inpatients : Underdiagnosed, often comorbid to neurodegenerative disorders and treatable. <i>Zeitschrift Fur Gerontologie Und Geriatrie</i> , <b>2019</b> , 52, 324-329 <sup>2-7</sup>		6
218	A roadmap for implementation of patient-centered digital outcome measures in Parkinson's disease obtained using mobile health technologies. <i>Movement Disorders</i> , <b>2019</b> , 34, 657-663	7	115
217	The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age. <i>Movement Disorders</i> , <b>2019</b> , 34, 676-681	7	28
216	Potential Markers of Progression in Idiopathic Parkinson's Disease Derived From Assessment of Circular Gait With a Single Body-Fixed-Sensor: A 5 Year Longitudinal Study. <i>Frontiers in Human Neuroscience</i> , <b>2019</b> , 13, 59	3-3	11
215	Progressive Gait Deficits in Parkinson's Disease: A Wearable-Based Biannual 5-Year Prospective Study. <i>Frontiers in Aging Neuroscience</i> , <b>2019</b> , 11, 22	5-3	23
214	Mit regelmäßigem Training wieder besser unterwegs. <i>Geriatric-Report</i> , <b>2019</b> , 14, 24-27	0	
213	Effects of Exergaming on Attentional Deficits and Dual-Tasking in Parkinson's Disease. <i>Frontiers in Neurology</i> , <b>2019</b> , 10, 646	4-1	9
212	Gait analysis with wearables predicts conversion to parkinson disease. <i>Annals of Neurology</i> , <b>2019</b> , 86, 357-367	9-4	57
211	Mobility Deficits Assessed With Mobile Technology: What Can We Learn From Brain Iron-Altered Animal Models?. <i>Frontiers in Neurology</i> , <b>2019</b> , 10, 833	4-1	
210	A combined miRNA-piRNA signature to detect Alzheimer's disease. <i>Translational Psychiatry</i> , <b>2019</b> , 9, 250	8-6	41
209	The Use of Virtual and Immersive Technology in Creating Personalized Multisensory Spaces for People Living With Dementia (SENSE-GARDEN): Protocol for a Multisite Before-After Trial. <i>JMIR Research Protocols</i> , <b>2019</b> , 8, e14096	2	8
208	Sarkopenie <b>2019</b> , 69-84		1
207	Internationale Klassifikation der Funktionsfähigkeit, Behinderung und Gesundheit (ICF) <b>2019</b> , 7-22		
206	Osteoporose beim Idiopathischem Parkinson-Syndrom: Risikopatienten erkennen, diagnostizieren und richtig behandeln. <i>Osteologie</i> , <b>2019</b> , 28, 268-273	0-2	
205	Metadata Concepts for Advancing the Use of Digital Health Technologies in Clinical Research. <i>Digital Biomarkers</i> , <b>2019</b> , 3, 116-132	7-1	16
204	Machine Learning to Detect Alzheimer's Disease from Circulating Non-coding RNAs. <i>Genomics, Proteomics and Bioinformatics</i> , <b>2019</b> , 17, 430-440	6-5	38
203	Prodromal features of Parkinson's disease: Self-reported symptoms versus clinically assessed signs. <i>Movement Disorders</i> , <b>2019</b> , 34, 144-146	7	2

202	Fall Risk in Relation to Individual Physical Activity Exposure in Patients with Different Neurodegenerative Diseases: a Pilot Study. <i>Cerebellum</i> , <b>2019</b> , 18, 340-348	4.3	14
201	A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein. <i>Journal of Parkinson's Disease</i> , <b>2019</b> , 9, 31-61	5.3	33
200	Parkinson's disease: evolution of cognitive impairment and CSF A $\beta$ profiles in a prospective longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2019</b> , 90, 165-170	5.5	7
199	Less Is More - Estimation of the Number of Strides Required to Assess Gait Variability in Spatially Confined Settings. <i>Frontiers in Aging Neuroscience</i> , <b>2018</b> , 10, 435	5.3	20
198	The association between objectively measured physical activity, depression, cognition, and health-related quality of life in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2018</b> , 48, 74-81	3.6	21
197	Effect of physical activity on cognitive flexibility, depression and RBD in healthy elderly. <i>Clinical Neurology and Neurosurgery</i> , <b>2018</b> , 165, 88-93	2	17
196	Parkinson disease in 2017: Changing views after 200 years of Parkinson disease. <i>Nature Reviews Neurology</i> , <b>2018</b> , 14, 70-72	15	7
195	The wide genetic landscape of clinical frontotemporal dementia: systematic combined sequencing of 121 consecutive subjects. <i>Genetics in Medicine</i> , <b>2018</b> , 20, 240-249	8.1	44
194	Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases. <i>Parkinsonism and Related Disorders</i> , <b>2018</b> , 46 Suppl 1, S53-S56	3.6	41
193	Brain-Area Specific White Matter Hyperintensities: Associations to Falls in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , <b>2018</b> , 8, 455-462	5.3	4
192	Are Hypometric Anticipatory Postural Adjustments Contributing to Freezing of Gait in Parkinson's Disease?. <i>Frontiers in Aging Neuroscience</i> , <b>2018</b> , 10, 36	5.3	38
191	Promising Metabolite Profiles in the Plasma and CSF of Early Clinical Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , <b>2018</b> , 10, 51	5.3	42
190	Effect of Fear of Falling on Turning Performance in Parkinson's Disease in the Lab and at Home. <i>Frontiers in Aging Neuroscience</i> , <b>2018</b> , 10, 78	5.3	23
189	Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany?. <i>Frontiers in Neurology</i> , <b>2018</b> , 9, 500	4.1	14
188	Metabolomic Profiles for Primary Progressive Multiple Sclerosis Stratification and Disease Course Monitoring. <i>Frontiers in Human Neuroscience</i> , <b>2018</b> , 12, 226	3.3	29
187	Hypermetabolism in the cerebellum and brainstem and cortical hypometabolism are independently associated with cognitive impairment in Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 45, 2387-2395	8.8	10
186	Bedeutung der Mobilitätsmessung [Zukunftsmusik oder sinnvoll?]. <i>Geriatric-Report</i> , <b>2018</b> , 13, 34-36	0	
185	What is Functional Mobility Applied to Parkinson's Disease?. <i>Journal of Parkinson's Disease</i> , <b>2018</b> , 8, 121-130	5.3	22



184	Polygenic load: Earlier disease onset but similar longitudinal progression in Parkinson's disease. <i>Movement Disorders</i> , <b>2018</b> , 33, 1349-1353	7	7
183	Arm swing asymmetry in overground walking. <i>Scientific Reports</i> , <b>2018</b> , 8, 12803	4.9	11
182	Cholinergic Pathway SNPs and Postural Control in 477 Older Adults. <i>Frontiers in Aging Neuroscience</i> , <b>2018</b> , 10, 260	5.3	1
181	miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson's disease. <i>Oncotarget</i> , <b>2018</b> , 9, 17455-17465	3.3	59
180	Moderate Frequency Resistance and Balance Training Do Not Improve Freezing of Gait in Parkinson's Disease: A Pilot Study. <i>Frontiers in Neurology</i> , <b>2018</b> , 9, 1084	4.1	7
179	Serum Inflammatory Profile for the Discrimination of Clinical Subtypes in Parkinson's Disease. <i>Frontiers in Neurology</i> , <b>2018</b> , 9, 1123	4.1	11
178	Gangstörungen bei Senioren: So klären Sie neurologische Ursachen ab. <i>Geriatric-Report</i> , <b>2018</b> , 13, 28-30	0	
177	How Mobile Health Technology and Electronic Health Records Will Change Care of Patients with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , <b>2018</b> , 8, S41-S45	5.3	17
176	Biomarkers of Neurodegeneration in Autoimmune-Mediated Encephalitis. <i>Frontiers in Neurology</i> , <b>2018</b> , 9, 668	4.1	27
175	Evaluation of cerebrospinal fluid proteins as potential biomarkers for early stage Parkinson's disease diagnosis. <i>PLoS ONE</i> , <b>2018</b> , 13, e0206536	3.7	18
174	Validation of a Lower Back "Wearable"-Based Sit-to-Stand and Stand-to-Sit Algorithm for Patients With Parkinson's Disease and Older Adults in a Home-Like Environment. <i>Frontiers in Neurology</i> , <b>2018</b> , 9, 652	4.1	18
173	Wearables for gait and balance assessment in the neurological ward - study design and first results of a prospective cross-sectional feasibility study with 384 inpatients. <i>BMC Neurology</i> , <b>2018</b> , 18, 114	3.1	23
172	Deterioration of executive dysfunction in elderly with REM sleep behavior disorder (RBD). <i>Neurobiology of Aging</i> , <b>2018</b> , 70, 242-246	5.6	9
171	Validation of a novel Montreal Cognitive Assessment scoring algorithm in non-demented Parkinson's disease patients. <i>Journal of Neurology</i> , <b>2018</b> , 265, 1976-1984	5.5	3
170	Inflammatory profile discriminates clinical subtypes in LRRK2-associated Parkinson's disease. <i>European Journal of Neurology</i> , <b>2017</b> , 24, 427-e6	6	30
169	The release and trans-synaptic transmission of Tau via exosomes. <i>Molecular Neurodegeneration</i> , <b>2017</b> , 12, 5	19	324
168	Home-Based Physical Behavior in Late Stage Parkinson Disease Dementia: Differences between Cognitive Subtypes. <i>Neurodegenerative Diseases</i> , <b>2017</b> , 17, 135-144	2.3	5
167	Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts. <i>Movement Disorders</i> , <b>2017</b> , 32, 1025-1034	7	53



166	Global, Yet Incomplete Overview of Cohort Studies in Parkinson's disease. <i>Journal of Parkinson's Disease</i> , <b>2017</b> , 7, 423-432	5.3	16
165	TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. <i>Human Mutation</i> , <b>2017</b> , 38, 297-309	4.7	66
164	Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles. <i>Movement Disorders</i> , <b>2017</b> , 32, 1780-1783	7	17
163	Dementia with Lewy bodies: cerebrospinal fluid suppresses neuronal network activity. <i>NeuroReport</i> , <b>2017</b> , 28, 1061-1065	1.7	3
162	Dual-Task Performance in GBA Parkinson's Disease. <i>Parkinson's Disease</i> , <b>2017</b> , 2017, 8582740	2.6	1
161	No relevant association of kinematic gait parameters with Health-related Quality of Life in Parkinson's disease. <i>PLoS ONE</i> , <b>2017</b> , 12, e0176816	3.7	9
160	Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease. <i>Movement Disorders</i> , <b>2017</b> , 32, 1401-1408	7	53
159	Progression markers of motor deficits in Parkinson's disease: A biannual 4-year prospective study. <i>Movement Disorders</i> , <b>2017</b> , 32, 1254-1256	7	7
158	SNPs in A $\beta$ clearance proteins: Lower CSF A $\beta$ levels and earlier onset of dementia in PD. <i>Neurology</i> , <b>2017</b> , 89, 2335-2340	6.5	10
157	Is the Assessment of 5 Meters of Gait with a Single Body-Fixed-Sensor Enough to Recognize Idiopathic Parkinson's Disease-Associated Gait?. <i>Annals of Biomedical Engineering</i> , <b>2017</b> , 45, 1266-1278	4.7	11
156	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , <b>2017</b> , 49, 214.e13-214.e15	5.6	10
155	Cerebrospinal Fluid Progranulin, but Not Serum Progranulin, Is Reduced in GRN-Negative Frontotemporal Dementia. <i>Neurodegenerative Diseases</i> , <b>2017</b> , 17, 83-88	2.3	18
154	Structural Ultrasound of the Medial Temporal Lobe in Alzheimer's Disease. <i>Ultraschall in Der Medizin</i> , <b>2017</b> , 38, 294-300	3.8	8
153	Associations between Early Markers of Parkinson's Disease and Sarcopenia. <i>Frontiers in Aging Neuroscience</i> , <b>2017</b> , 9, 53	5.3	24
152	Evidence for a Selectively Regulated Prioritization Shift Depending on Walking Situations in Older Adults. <i>Frontiers in Aging Neuroscience</i> , <b>2017</b> , 9, 75	5.3	8
151	Gait Is Associated with Cognitive Flexibility: A Dual-Tasking Study in Healthy Older People. <i>Frontiers in Aging Neuroscience</i> , <b>2017</b> , 9, 154	5.3	16
150	White Matter Changes-Related Gait and Executive Function Deficits: Associations with Age and Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , <b>2017</b> , 9, 213	5.3	7
149	Algorithm for Turning Detection and Analysis Validated under Home-Like Conditions in Patients with Parkinson's Disease and Older Adults using a 6 Degree-of-Freedom Inertial Measurement Unit at the Lower Back. <i>Frontiers in Neurology</i> , <b>2017</b> , 8, 135	4.1	20

148	Validation of a Step Detection Algorithm during Straight Walking and Turning in Patients with Parkinson's Disease and Older Adults Using an Inertial Measurement Unit at the Lower Back. <i>Frontiers in Neurology</i> , <b>2017</b> , 8, 457	4.1	43
147	Parkinson-Therapie beim alten Patienten. <i>Neurotransmitter</i> , <b>2017</b> , 28, 40-47	0.1	
146	New methods for the assessment of Parkinson's disease (2005 to 2015): A systematic review. <i>Movement Disorders</i> , <b>2016</b> , 31, 1283-92	7	92
145	Association of Plasma A $\beta$ 0 Peptides, But Not A $\beta$ 2, with Coronary Artery Disease and Diabetes Mellitus. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 52, 161-9	4.3	10
144	The FARSEEING real-world fall repository: a large-scale collaborative database to collect and share sensor signals from real-world falls. <i>European Review of Aging and Physical Activity</i> , <b>2016</b> , 13, 8	6.5	43
143	Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs. <i>Alzheimer's Research and Therapy</i> , <b>2016</b> , 8, 42	9	10
142	Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. <i>Neuron</i> , <b>2016</b> , 91, 56-66	13.9	178
141	A systematic review of the characteristics and validity of monitoring technologies to assess Parkinson's disease. <i>Journal of NeuroEngineering and Rehabilitation</i> , <b>2016</b> , 13, 24	5.3	120
140	Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy. <i>Movement Disorders</i> , <b>2016</b> , 31, 742-7	7	22
139	Validating Alzheimer's disease micro RNAs using next-generation sequencing. <i>Alzheimer's and Dementia</i> , <b>2016</b> , 12, 565-76	1.2	44
138	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. <i>Neurobiology of Aging</i> , <b>2016</b> , 38, 214.e7-214.e10	5.6	49
137	Health-Related Quality of Life in patients with Parkinson's disease--A systematic review based on the ICF model. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2016</b> , 61, 26-34	9	95
136	Continuous leg dyskinesia assessment in Parkinson's disease -clinical validity and ecological effect. <i>Parkinsonism and Related Disorders</i> , <b>2016</b> , 26, 41-6	3.6	24
135	Altered dendritic cell subset distribution in patients with Parkinson's disease: Impact of CMV serostatus. <i>Journal of Neuroimmunology</i> , <b>2016</b> , 290, 60-5	3.5	11
134	Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. <i>American Journal of Human Genetics</i> , <b>2016</b> , 98, 500-513	11	225
133	In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin. <i>Neurobiology of Disease</i> , <b>2016</b> , 91, 59-68	7.5	52
132	Pilot whole-exome sequencing of a German early-onset Alzheimer's disease cohort reveals a substantial frequency of PSEN2 variants. <i>Neurobiology of Aging</i> , <b>2016</b> , 37, 208.e11-208.e17	5.6	24
131	Ambulatory Activity Components Deteriorate Differently across Neurodegenerative Diseases: A Cross-Sectional Sensor-Based Study. <i>Neurodegenerative Diseases</i> , <b>2016</b> , 16, 317-23	2.3	9

130	GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body Dementia. <i>PLoS ONE</i> , <b>2016</b> , 11, e0149349	3-7	22
129	Quantitative Timed-Up-and-Go Parameters in Relation to Cognitive Parameters and Health-Related Quality of Life in Mild-to-Moderate Parkinson's Disease. <i>PLoS ONE</i> , <b>2016</b> , 11, e0151997	3-7	24
128	Serum Levels of Progranulin Do Not Reflect Cerebrospinal Fluid Levels in Neurodegenerative Disease. <i>Current Alzheimer Research</i> , <b>2016</b> , 13, 654-62	3	22
127	Limited Effect of Dopaminergic Medication on Straight Walking and Turning in Early-to-Moderate Parkinson's Disease during Single and Dual Tasking. <i>Frontiers in Aging Neuroscience</i> , <b>2016</b> , 8, 4	5-3	17
126	Aiming for Study Comparability in Parkinson's Disease: Proposal for a Modular Set of Biomarker Assessments to be Used in Longitudinal Studies. <i>Frontiers in Aging Neuroscience</i> , <b>2016</b> , 8, 121	5-3	10
125	Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons Learned. <i>Frontiers in Aging Neuroscience</i> , <b>2016</b> , 8, 147	5-3	23
124	Dual Tasking for the Differentiation between Depression and Mild Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , <b>2016</b> , 8, 235	5-3	12
123	Cognitive Performance Patterns in Healthy Individuals with Substantia Nigra Hyperechogenicity and Early Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , <b>2016</b> , 8, 271	5-3	5
122	Inflammatory profile in LRRK2-associated prodromal and clinical PD. <i>Journal of Neuroinflammation</i> , <b>2016</b> , 13, 122	10-1	33
121	A Viewpoint on Wearable Technology-Enabled Measurement of Wellbeing and Health-Related Quality of Life in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , <b>2016</b> , 6, 279-87	5-3	30
120	Intra-Rater, Inter-Rater and Test-Retest Reliability of an Instrumented Timed Up and Go (iTUG) Test in Patients with Parkinson's Disease. <i>PLoS ONE</i> , <b>2016</b> , 11, e0151881	3-7	47
119	Insulin-Like Growth Factor 1 (IGF-1) in Parkinson's Disease: Potential as Trait-, Progression- and Prediction Marker and Confounding Factors. <i>PLoS ONE</i> , <b>2016</b> , 11, e0150552	3-7	21
118	Technology in Parkinson's disease: Challenges and opportunities. <i>Movement Disorders</i> , <b>2016</b> , 31, 1272-827		305
117	Freezing of Swallowing. <i>Movement Disorders Clinical Practice</i> , <b>2016</b> , 3, 490-493	2-2	7
116	Twelve-week sensor assessment in Parkinson's disease: Impact on quality of life. <i>Movement Disorders</i> , <b>2016</b> , 31, 1337-8	7	14
115	A clinical view on the development of technology-based tools in managing Parkinson's disease. <i>Movement Disorders</i> , <b>2016</b> , 31, 1263-71	7	96
114	Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 1270-1272	5-5	49
113	Motor dual-tasking deficits predict falls in Parkinson's disease: A prospective study. <i>Parkinsonism and Related Disorders</i> , <b>2016</b> , 26, 73-7	3-6	53

112	Validation of conversion between mini-mental state examination and montreal cognitive assessment. <i>Movement Disorders</i> , <b>2016</b> , 31, 593-6	7	37
111	Reasons for mild parkinsonian signs - which constellation may indicate neurodegeneration?. <i>Parkinsonism and Related Disorders</i> , <b>2015</b> , 21, 126-30	3.6	14
110	The relation of SMI and the VSEP in a risk sample for neurodegenerative disorders. <i>Journal of Neural Transmission</i> , <b>2015</b> , 122, 1167-74	4.3	7
109	Quantitative motor assessment of dyskinesias in Parkinson's disease. <i>Journal of Neural Transmission</i> , <b>2015</b> , 122, 1271-8	4.3	4
108	Gait velocity and step length at baseline predict outcome of Nordic walking training in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2015</b> , 21, 413-6	3.6	16
107	CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. <i>Alzheimer's and Dementia</i> , <b>2015</b> , 11, 1306-15	1.2	87
106	Quantitative home-based assessment of Parkinson's symptoms: the SENSE-PARK feasibility and usability study. <i>BMC Neurology</i> , <b>2015</b> , 15, 89	3.1	52
105	Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study. <i>Parkinsonism and Related Disorders</i> , <b>2015</b> , 21, 1427-34	3.6	16
104	Accelerometer-based quantitative analysis of axial nocturnal movements differentiates patients with Parkinson's disease, but not high-risk individuals, from controls. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2015</b> , 86, 32-7	5.5	25
103	Time- and frequency-domain parameters of heart rate variability and sympathetic skin response in Parkinson's disease. <i>Journal of Neural Transmission</i> , <b>2015</b> , 122, 419-25	4.3	37
102	Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption. <i>Molecular Psychiatry</i> , <b>2015</b> , 20, 647-656	15.1	167
101	Increased cerebrospinal fluid calpain activity and microparticle levels in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2015</b> , 11, 465-74	1.2	20
100	Clinical Parameters and Tools for Home-Based Assessment of Parkinson's Disease: Results from a Delphi study. <i>Journal of Parkinson's Disease</i> , <b>2015</b> , 5, 281-90	5.3	11
99	Association between vestibulo-ocular reflex suppression, balance, gait, and fall risk in ageing and neurodegenerative disease: protocol of a one-year prospective follow-up study. <i>BMC Neurology</i> , <b>2015</b> , 15, 192	3.1	11
98	Participatory design in Parkinson's research with focus on the symptomatic domains to be measured. <i>Journal of Parkinson's Disease</i> , <b>2015</b> , 5, 187-96	5.3	16
97	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , <b>2015</b> , 6, 216	4.1	31
96	Digitomotography in Parkinson's disease: a cross-sectional and longitudinal study. <i>PLoS ONE</i> , <b>2015</b> , 10, e0123914	3.7	17
95	Progressive Supranuclear Palsy and Dementia <b>2015</b> , 147-157		

94	Methods in Neuroepidemiology Characterization of European Longitudinal Cohort Studies in Parkinson's Disease--Report of the JPND Working Group BioLoC-PD. <i>Neuroepidemiology</i> , <b>2015</b> , 45, 282-974	5.4	16
93	Total tau is increased, but phosphorylated tau not decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis. <i>Neurobiology of Aging</i> , <b>2015</b> , 36, 1072-4	5.6	25
92	GBA-associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study. <i>Movement Disorders</i> , <b>2015</b> , 30, 407-11	7	135
91	The brain response to peripheral insulin declines with age: a contribution of the blood-brain barrier?. <i>PLoS ONE</i> , <b>2015</b> , 10, e0126804	3.7	50
90	Age and Vascular Burden Determinants of Cortical Hemodynamics Underlying Verbal Fluency. <i>PLoS ONE</i> , <b>2015</b> , 10, e0138863	3.7	17
89	A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. <i>Movement Disorders</i> , <b>2014</b> , 29, 470-8	7	201
88	Prodromal features for Parkinson's disease--baseline data from the TREND study. <i>European Journal of Neurology</i> , <b>2014</b> , 21, 766-72	6	76
87	Technical and clinical view on ambulatory assessment in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , <b>2014</b> , 130, 139-47	3.8	38
86	Highly potent soluble amyloid- $\beta$ seeds in human Alzheimer brain but not cerebrospinal fluid. <i>Brain</i> , <b>2014</b> , 137, 2909-2915	11.2	52
85	Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. <i>Nature Genetics</i> , <b>2014</b> , 46, 989-93	36.3	1261
84	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , <b>2014</b> , 128, 397-410	14.3	83
83	Evidence for altered transport of insulin across the blood-brain barrier in insulin-resistant humans. <i>Acta Diabetologica</i> , <b>2014</b> , 51, 679-81	3.9	79
82	Comparable autoantibody serum levels against amyloid- and inflammation-associated proteins in Parkinson's disease patients and controls. <i>PLoS ONE</i> , <b>2014</b> , 9, e88604	3.7	28
81	Risk for femoral fractures in Parkinson's disease patients with and without severe functional impairment. <i>PLoS ONE</i> , <b>2014</b> , 9, e97073	3.7	26
80	Naturally occurring alpha-synuclein autoantibodies in Parkinson's disease: sources of (error) variance in biomarker assays. <i>PLoS ONE</i> , <b>2014</b> , 9, e114566	3.7	16
79	A neurodegenerative vascular burden index and the impact on cognition. <i>Frontiers in Aging Neuroscience</i> , <b>2014</b> , 6, 161	5.3	13
78	Instrumented functional reach test differentiates individuals at high risk for Parkinson's disease from controls. <i>Frontiers in Aging Neuroscience</i> , <b>2014</b> , 6, 286	5.3	11
77	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. <i>Human Molecular Genetics</i> , <b>2014</b> , 23, 6139-46	5.6	152

76	Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. <i>Movement Disorders</i> , <b>2014</b> , 29, 479-87	7	106
75	In vivo markers of Parkinson's disease and dementia with Lewy bodies: current value of the 5G4 $\beta$ synuclein antibody. <i>Acta Neuropathologica</i> , <b>2014</b> , 128, 893-5	14.3	6
74	Comment: why do nondopaminergic features in Parkinson disease matter?. <i>Neurology</i> , <b>2014</b> , 82, 417	6.5	6
73	Post-cueing deficits with maintained cueing benefits in patients with Parkinson's disease dementia. <i>Frontiers in Neurology</i> , <b>2014</b> , 5, 236	4.1	2
72	High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia. <i>Alzheimer's and Dementia</i> , <b>2014</b> , 10, 530-540.e1	1.2	15
71	Mild parkinsonian signs in the elderly--is there an association with PD? Cross-sectional findings in 992 individuals. <i>PLoS ONE</i> , <b>2014</b> , 9, e92878	3.7	21
70	Emerging therapies for gait disability and balance impairment: promises and pitfalls. <i>Movement Disorders</i> , <b>2013</b> , 28, 1576-86	7	34
69	Quantitative wearable sensors for objective assessment of Parkinson's disease. <i>Movement Disorders</i> , <b>2013</b> , 28, 1628-37	7	216
68	Development of a standard fall data format for signals from body-worn sensors : the FARSEEING consensus. <i>Zeitschrift Fur Gerontologie Und Geriatrie</i> , <b>2013</b> , 46, 720-6	2.7	19
67	Aging-related cortical reorganization of verbal fluency processing: a functional near-infrared spectroscopy study. <i>Neurobiology of Aging</i> , <b>2013</b> , 34, 439-50	5.6	63
66	A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. <i>Human Mutation</i> , <b>2013</b> , 34, 363-73	4.7	208
65	The PRIPS study: screening battery for subjects at risk for Parkinson's disease. <i>European Journal of Neurology</i> , <b>2013</b> , 20, 102-8	6	91
64	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , <b>2013</b> , 9, 251-61	1.2	289
63	Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. <i>Lancet Neurology</i> , <b>2013</b> , 12, 514-24	24.1	108
62	SNCA: major genetic modifier of age at onset of Parkinson's disease. <i>Movement Disorders</i> , <b>2013</b> , 28, 1217-21	28	
61	Evaluation of progression markers in the premotor phase of Parkinson's disease: the progression markers in the premotor phase study. <i>Neuroepidemiology</i> , <b>2013</b> , 41, 174-82	5.4	20
60	No association of GBA mutations and multiple system atrophy. <i>European Journal of Neurology</i> , <b>2013</b> , 20, e61-2	6	24
59	Differentiation of progressive supranuclear palsy: clinical, imaging and laboratory tools. <i>Acta Neurologica Scandinavica</i> , <b>2013</b> , 127, 362-70	3.8	29



58	A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. <i>JAMA Neurology</i> , <b>2013</b> , 70, 727-35	17.2	285
57	Immune profiling in blood identifies sTNF-R1 performing comparably well as biomarker panels for classification of Alzheimer's disease patients. <i>Journal of Alzheimer's Disease</i> , <b>2013</b> , 34, 367-75	4.3	17
56	Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study. <i>PLoS ONE</i> , <b>2013</b> , 8, e73094	3.7	124
55	Biomarkers in Alzheimer's disease and lewy body disorders with dementia. <i>International Journal of Alzheimer's Disease</i> , <b>2013</b> , 2013, 473181	3.7	
54	Altered serum IgG levels to $\beta$ synuclein in dementia with Lewy bodies and Alzheimer's disease. <i>PLoS ONE</i> , <b>2013</b> , 8, e64649	3.7	22
53	Clinical characteristics with an impact on ADL functions of PD patients with cognitive impairment indicative of dementia. <i>PLoS ONE</i> , <b>2013</b> , 8, e82902	3.7	9
52	Fluorodeoxyglucose positron emission tomography in Richardson's syndrome and progressive supranuclear palsy-parkinsonism. <i>Movement Disorders</i> , <b>2012</b> , 27, 151-5	7	26
51	Cerebrospinal fluid fatty acids in glucocerebrosidase-associated Parkinson's disease. <i>Movement Disorders</i> , <b>2012</b> , 27, 288-92	7	15
50	Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. <i>Journal of Neural Transmission</i> , <b>2012</b> , 119, 39-52	4.3	54
49	Reply: Presyndromic phase: Proposal for a new term for an emerging concept. <i>Movement Disorders</i> , <b>2012</b> , 27, 1584-1585	7	
48	Proposal for a multiphase fall model based on real-world fall recordings with body-fixed sensors. <i>Zeitschrift Fur Gerontologie Und Geriatrie</i> , <b>2012</b> , 45, 707-15	2.7	41
47	Using multi-dimensional dynamic time warping for TUG test instrumentation with inertial sensors <b>2012</b> ,		10
46	Screening in ALS and FTD patients reveals 3 novel UBQLN2 mutations outside the PXX domain and a pure FTD phenotype. <i>Neurobiology of Aging</i> , <b>2012</b> , 33, 2949.e13-7	5.6	69
45	Protein clearance mechanisms of alpha-synuclein and amyloid-Beta in lewy body disorders. <i>International Journal of Alzheimer's Disease</i> , <b>2012</b> , 2012, 391438	3.7	25
44	Motor signs in the prodromal phase of Parkinson's disease. <i>Movement Disorders</i> , <b>2012</b> , 27, 627-33	7	54
43	Longitudinal changes of nerve conduction velocity, distal motor latency, compound motor action potential duration, and skin temperature during prolonged exposure to cold in a climate chamber. <i>International Journal of Neuroscience</i> , <b>2012</b> , 122, 528-31	2	3
42	S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF- $\alpha$ pathway. <i>Brain</i> , <b>2012</b> , 135, 3336-47	11.2	118
41	Lowered serum amyloid- $\beta$ 42 autoantibodies in individuals with lifetime depression. <i>Journal of Alzheimer's Disease</i> , <b>2012</b> , 32, 95-100	4.3	7



40	Impaired trunk stability in individuals at high risk for Parkinson's disease. <i>PLoS ONE</i> , <b>2012</b> , 7, e32240	3.7	58
39	Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia. <i>PLoS ONE</i> , <b>2012</b> , 7, e48042	3.7	18
38	Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. <i>Nature Genetics</i> , <b>2011</b> , 43, 699-705	36.3	386
37	Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias. <i>Journal of Alzheimer's Disease</i> , <b>2011</b> , 26, 171-9	4.3	48
36	Pre-motor signs of PD are related to SN hyperechogenicity assessed by TCS in an elderly population. <i>Neurobiology of Aging</i> , <b>2011</b> , 32, 1599-606	5.6	35
35	Influence of different cut-off values on the diagnosis of mild cognitive impairment in Parkinson's disease. <i>Parkinson's Disease</i> , <b>2011</b> , 2011, 540843	2.6	29
34	Poor trail making test performance is directly associated with altered dual task prioritization in the elderly--baseline results from the TREND study. <i>PLoS ONE</i> , <b>2011</b> , 6, e27831	3.7	58
33	Serum and cerebrospinal fluid uric acid levels in lewy body disorders: associations with disease occurrence and amyloid- $\beta$ pathway. <i>Journal of Alzheimer's Disease</i> , <b>2011</b> , 27, 119-26	4.3	37
32	In vivo comparison of Richardson's syndrome and progressive supranuclear palsy-parkinsonism. <i>Journal of Neural Transmission</i> , <b>2011</b> , 118, 1191-7	4.3	26
31	Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases. <i>Movement Disorders</i> , <b>2011</b> , 26, 176-81	7	36
30	Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. <i>Movement Disorders</i> , <b>2011</b> , 26, 2335-42	7	55
29	Increased [11C]PIB-PET levels in inclusion body myositis are indicative of amyloid beta deposition. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2011</b> , 82, 1060-2	5.5	13
28	Comparison of acceleration signals of simulated and real-world backward falls. <i>Medical Engineering and Physics</i> , <b>2011</b> , 33, 368-73	2.4	111
27	Serum insulinlike growth factor 1 as possible marker for risk and early diagnosis of Parkinson disease. <i>Archives of Neurology</i> , <b>2011</b> , 68, 925-31		33
26	Decreased $\beta$ synuclein serum levels in patients with Lewy body dementia compared to Alzheimer's disease patients and control subjects. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2011</b> , 31, 413-6	2.6	24
25	Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. <i>Archives of Neurology</i> , <b>2011</b> , 68, 932-7		131
24	Nepriylsin activity in cerebrospinal fluid is associated with dementia and amyloid- $\beta$ 2 levels in Lewy body disease. <i>Journal of Alzheimer's Disease</i> , <b>2010</b> , 22, 933-8	4.3	22
23	The human G93A SOD1 phenotype closely resembles sporadic amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2010</b> , 81, 764-7	5.5	23

22	Macrophage colony-stimulating factor (M-CSF) in plasma and CSF of patients with mild cognitive impairment and Alzheimer's disease. <i>Current Alzheimer Research</i> , <b>2010</b> , 7, 409-14	3	27
21	Progressive secondary neurodegeneration and microcalcification co-occur in osteopontin-deficient mice. <i>American Journal of Pathology</i> , <b>2010</b> , 177, 829-39	5.8	16
20	The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease. <i>Journal of Alzheimer's Disease</i> , <b>2010</b> , 19, 937-42	4.3	26
19	Biomarkers of Alzheimer's and Parkinson's Disease <b>2010</b> , 89-117		
18	Improvement of balance after audio-biofeedback. A 6-week intervention study in patients with progressive supranuclear palsy. <i>Zeitschrift Fur Gerontologie Und Geriatrie</i> , <b>2010</b> , 43, 224-8	2.7	31
17	Clinical and dual-tasking aspects in frequent and infrequent fallers with progressive supranuclear palsy. <i>Movement Disorders</i> , <b>2010</b> , 25, 1040-6	7	23
16	Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly. <i>Movement Disorders</i> , <b>2010</b> , 25, 1464-9	7	37
15	Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. <i>Neurobiology of Disease</i> , <b>2009</b> , 34, 107-12	7.5	158
14	No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases. <i>Neurobiology of Disease</i> , <b>2009</b> , 35, 296-301	7.5	14
13	Progression of Parkinson's disease in the clinical phase: potential markers. <i>Lancet Neurology</i> , <b>2009</b> , 8, 1158-71	24.1	208
12	Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration-[18F]FDG-PET. <i>Movement Disorders</i> , <b>2009</b> , 24, 1504-11	7	40
11	A single-nucleotide polymorphism of the osteopontin gene may contribute to a susceptibility to Lewy body disease. <i>Journal of Neural Transmission</i> , <b>2009</b> , 116, 599-605	4.3	13
10	Microcalcification after excitotoxicity is enhanced in transgenic mice expressing parvalbumin in all neurones, may commence in neuronal mitochondria and undergoes structural modifications over time. <i>Neuropathology and Applied Neurobiology</i> , <b>2009</b> , 35, 165-77	5.2	13
9	Glial cell-line derived neurotrophic factor (GDNF) concentrations in cerebrospinal fluid and serum of patients with early Alzheimer's disease and normal controls. <i>Journal of Alzheimer's Disease</i> , <b>2009</b> , 18, 331-7	4.3	60
8	[11C]PIB binding in Parkinson's disease dementia. <i>NeuroImage</i> , <b>2008</b> , 39, 1027-33	7.9	120
7	Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. <i>Neurobiology of Disease</i> , <b>2007</b> , 25, 473-82	7.5	91
6	BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. <i>Journal of Psychiatric Research</i> , <b>2007</b> , 41, 387-94	5.2	204
5	Wie sollen wir Patienten mit Demenz behandeln? Die ethisch problematische Funktion der Antidementiva. <i>Ethik in Der Medizin</i> , <b>2007</b> , 19, 270-280	0.5	1

4	Treatment of dementia in parkinsonian syndromes with cholinesterase inhibitors. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2007</b> , 23, 351-67	2.6	10
3	GABA(B) receptor expression and cellular localization in gerbil hippocampus after transient global ischemia. <i>Neuroscience Letters</i> , <b>2006</b> , 395, 118-23	3.3	20
2	Ectopic parvalbumin expression in mouse forebrain neurons increases excitotoxic injury provoked by ibotenic acid injection into the striatum. <i>Experimental Neurology</i> , <b>2004</b> , 186, 78-88	5.7	26
1	Cerebellar rTMS in PSP: a double blind sham-controlled study using mobile health technology		1